Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 5, 2019. The document serves as a transaction notification regarding a specific insider trading event rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific executive transaction:
- Transaction Type: Cash payout following the vesting of an award under the GlaxoSmithKline Deferred Investment Award plan.
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Volume: 6,700.785 notional ADSs.
- Price: $40.39 per ADS.
- Value: Gross cash payout of £270,644.71 (less applicable tax withholding).
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely documents a routine equity compensation event for a specific individual.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of a transaction executed on March 4, 2019.
Important Facts for Investors
- Executive Involved: Mr. B. McNamara, CEO of GSK Consumer Healthcare.
- Transaction Date: March 4, 2019.
- Award Origin: The transaction resulted from an award made on March 2, 2015.
- Scope Limitation: This document does not contain quarterly or annual financial results for GSK Plc.